靶向ERK1/2抑制中性粒细胞胞外诱捕网介导的肌炎相关间质性肺病促炎促纤维化效应
研究探讨ERK1/2信号通路在肌炎相关间质性肺病中NETs介导的促炎促纤维化作用。在IIM-ILD患者肺组织及EAM和MAILD小鼠模型中观察到ERK1/2激活和NETs浸润,NETs通过激活ERK1/2诱导EMT和促炎因子释放。ERK1/2抑制剂U0126在体内外减轻NETs诱导的EMT和炎症反应,并减少MAILD模型肺部炎症浸润和NETs形成。
要点
- IIM-ILD患者肺组织及EAM、MAILD小鼠模型中ERK1/2信号通路被激活。
- NETs通过激活ERK1/2诱导上皮间质转化和促炎因子释放。
- ERK1/2抑制剂U0126减轻MAILD模型肺部炎症浸润和NETs形成。
核心结论
- NETs通过激活ERK1/2信号通路介导促炎促纤维化过程,促进肌炎相关间质性肺病进展。
- 靶向ERK1/2可有效抑制该致病级联反应,为临床治疗提供新策略。
研究设计与样本
- 收集IIM-ILD患者肺组织及EAM和MAILD小鼠模型肺组织。
- 采用免疫组化、蛋白质印迹、免疫荧光和转录组测序分析ERK1/2激活、NETs浸润及EMT相关标志物表达。
- 在体内外应用ERK1/2抑制剂U0126进行干预验证。
主要发现
- IIM-ILD患者肺组织及EAM和MAILD小鼠模型中ERK1/2信号通路被激活。
- EAM和MAILD小鼠肺组织可见大量NETs浸润。
- NETs通过激活ERK1/2诱导EMT和促炎因子释放。
- 抑制NETs形成可减弱ERK1/2磷酸化及下游纤维化过程。
- U0126减轻NETs诱导的EMT和炎症反应,并减少MAILD模型肺部炎症浸润和NETs形成。
临床怎么用
- 靶向ERK1/2信号通路可能成为肌炎相关间质性肺病的治疗新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to investigate the mechanism and therapeutic potential of targeting the extracellular signal-regulated kinase 1/2 (ERK1/2) signalling pathway in myositis-associated interstitial lung disease, focusing on its role in neutrophil extracellular traps (NETs)-mediated pro-inflammatory and pro-fibrotic processes. METHODS: Lung tissue samples were collected from patients with idiopathic inflammatory myopathy-associated ILD (IIM-ILD) and from mice with experimental autoimmune myositis (EAM) and a myositis-associated interstitial lung disease model (MAILD). Multiple experimental techniques, including immunohistochemistry, western blotting, immunofluorescence and transcriptome sequencing were employed to analyse ERK1/2 activation, NETs infiltration and the expression of epithelial-mesenchymal transition (EMT)-related markers. The ERK1/2 inhibitor U0126 was applied both in vivo and in vitro for interventional validation. RESULTS: The ERK1/2 signalling pathway was activated in the lung tissues of IIM-ILD patients and in the EAM and MAILD mouse models. Substantial NETs infiltration was observed in the lung tissues of EAM and MAILD mice. NETs induced EMT and the release of pro-inflammatory factors by activating ERK1/2. Inhibiting NETs formation attenuated ERK1/2 phosphorylation and the downstream fibrotic process. Administration of the ERK1/2 inhibitor U0126 not only effectively alleviated NETs-induced EMT and inflammatory responses but also significantly reduced pulmonary inflammation infiltration and NETs formation in the MAILD model. CONCLUSION: NETs-mediated pro-inflammatory and pro-fibrotic processes contribute to the progression of myositis-associated interstitial lung disease by activating the ERK1/2 signalling pathway. Targeting ERK1/2 effectively inhibits this pathogenic cascade, providing a novel strategy for clinical treatment.
引用
- Chai H, Yang J, Li W, et al. Targeting ERK1/2 attenuates neutrophil extracellular traps-mediated pro-inflammatory and pro-fibrotic effects in myositis-associated interstitial lung disease. Rheumatology (Oxford). 2026. PMID: 42458217. doi:10.1093/rheumatology/keag367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。